Use of anti-PD-1 and anti-PD-L1 antibodies for treatment of multiple cancers are increasing at a fast rate, but its benefit in NSCLC seems to be limited to a subset of patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.